ArticleThe FEBS journal2026
Shikimate pathway disruption in yeast induces metabolite self-assembly into toxic aggregates.
Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The shikimate pathway in Saccharomyces cerevisiae is pivotal for the biosynthesis of aromatic amino acids, which are essential for protein synthesis and cellular homeostasis. Here, we investigated the regulatory mechanisms within this pathway, focusing on the two key enzymes: phospho-2-dehydro-3-deoxyheptonate aldolase, tyrosine-inhibited (Aro4) and phospho-2-dehydro-3-deoxyheptonate aldolase, phenylalanine-inhibited (Aro3). Deletion of either the ARO4 or ARO3 genes led to significant intracellular accumulation of phenylalanine or tyrosine, respectively, upon feeding with the corresponding metabolite. Remarkably, we discovered that this metabolite accumulation promotes the formation of amyloid-like assemblies within cells, as evidenced by amyloid-specific staining and antibody recognition towards phenylalanine and tyrosine assemblies. These assemblies strongly correlated with reduced cell viability. Treatment with common amyloid inhibitors significantly mitigated the formation of these toxic assemblies, improving cell growth, and viability in the mutant strains. Additionally, although overexpression of ARO3 in the aro4Δ background partially rescued the growth phenotype, combining ARO3 overexpression with trimethylamine N-oxide (TMAO) treatment provided an additive growth rescue effect. Our findings highlight the role of cellular self-assembly in regulating the shikimate pathway and reveal a previously unknown link between metabolic dysregulation and the formation of toxic amyloid-like structures. This discovery offers new insights into inherited metabolic disorders and potential therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.